{
    "clinical_study": {
        "@rank": "55242", 
        "arm_group": [
            {
                "arm_group_label": "Period 3: BI 113608+Voriconazole", 
                "arm_group_type": "Experimental", 
                "description": "tablets with 240 ml water"
            }, 
            {
                "arm_group_label": "Period 2: BI 113608+Ketoconazole", 
                "arm_group_type": "Experimental", 
                "description": "tablets with 240 ml water"
            }, 
            {
                "arm_group_label": "Period 1: BI 113608", 
                "arm_group_type": "Experimental", 
                "description": "tablets with 240 ml water"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to investigate the relative bioavailability of a\n      single oral dose of BI 113608 without and with ketoconazole and voriconazole at steady\n      state. The assessment of safety and tolerability of BI 113608 administered alone and upon\n      co-administration will be an additional objective of this trial."
        }, 
        "brief_title": "Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. Healthy male subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787032", 
            "org_study_id": "1314.7", 
            "secondary_id": "2012-002538-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "Period 3: BI 113608+Voriconazole", 
                "description": "tablet", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Period 2: BI 113608+Ketoconazole", 
                "description": "tablet", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Period 1: BI 113608", 
                "description": "tablet", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Period 2: BI 113608+Ketoconazole", 
                "description": "tablet", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Period 3: BI 113608+Voriconazole", 
                "description": "tablet", 
                "intervention_name": "Voriconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ketoconazole", 
                "Voriconazole"
            ]
        }, 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ingelheim", 
                    "country": "Germany"
                }, 
                "name": "1314.7.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Relative Bioavailability of Single Oral Dose of BI 113608 When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole or Voriconazole in Healthy Male Subjects (an Open-label, Randomised, Three-period Cross-over Trial)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }, 
            {
                "measure": "Incidence of Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "at least 4 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787032"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }, 
            {
                "measure": "tmax (time from dosing to maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }, 
            {
                "measure": "t1/2 (terminal half-life of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}